Y. Berkun, E. Eisenstein, E. Ben-Chetrit
Department of Pediatrics, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel. firstname.lastname@example.org
2012 Vol.30, N°3 ,Suppl.72 - PI 0090, PF 0095
Free to view (click on article PDF icon to read the article)
The last two years have been marked by many studies trying to better characterize the clinical features of FMF in children and proposal of new treatment for those who are resistant to colchicine. In addition, many studies tried to address the potential effect of genetic modifiers on FMF and the potential effect of MEFV mutations on other inflammatory diseases. The main points arose from these studies include a breakthrough in the therapeutic approach for FMF and the lack of consistency regarding the reciprocal effect of MEFV mutations on other diseases and the effect of genetic modifiers on FMF. The highlights of these studies, their potential clinical implications and the unmet needs, which are still to be addressed, are summarised in this review.
PMID: 23009752 [PubMed]
Received: 30/08/2012 - Accepted : 30/08/2012 - In Press: 25/09/2012 - Published: 19/11/2012